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tor of p53–MDM2 interaction), chalcones 3 and 4 bind to the p53-binding site of MDM2. The
results here presented will be valuable for the structure-based design of novel and potent p53–
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Despite the diversity of genes involved in tumorigenesis, the tumor
suppressor protein p53 stands out as a master regulator of various sig-
naling pathways involved in this process. p53 activation can prevent
the proliferation of tumor cells by induction of cell growth arrest,
senescence or apoptosis, modulation of the tumor stroma, as well as
by inhibition of invasion and metastasis (Vousden and Prives, 2009).
The p53 tumor suppressor pathway is one of the most frequently
altered in human cancers. About half of all cancers retain wild-type
p53, nevertheless the p53 pathway is inactivated due to the overexpres-
sion of the main endogenous negative regulator, murine double minute
2 (MDM2). MDM2 binds p53 and negatively regulates its activity, by
direct inhibition of p53 transcriptional activity and enhancement of
p53 degradation via the ubiquitin–proteasome pathway. The re-
establishment of p53 activity by inhibition of its interaction with
MDM2 represents an appealing therapeutic strategy for many wt
p53 tumors with overexpression of MDM2, and has therefore been a
focus of large effort in drug discovery (Kamal et al., 2012; Paiva
et al., 2013; Selivanova, 2014; Wang et al., 2012).
Flavonoids have long been recognized for their broad spectrum of
pharmacological activities (Erlund, 2004; Ferreira et al., 2014; Smejkal,
2014). Among this family of compounds, chalcones represent one of
the major classes of naturally occurring products possessing a wide
range of biological activities, namely antioxidant, antimicrobial,
antiprotozoal, antimalarial, antiulcer, antihistaminic, anti-
inflammatory, and antitumor activities (Mahapatra et al., 2015; Sahu
et al., 2012; Singh et al., 2014). Some reports have related the antitu-
mor activities of chalcones with activation of a p53-dependent pathway
(Lai et al., 2014; Rao et al., 2010; Zhou and Ho, 2014). Additionally, it
has been demonstrated that some chalcone derivatives can disrupt the
p53–MDM2 complex with the subsequent release of p53 (Stoll et al.,
2001). Together, these studies support the idea that chalcone may
represent a promising chemical scaffold to search for new inhibitors
of p53–MDM2 interaction.
Herein, potential novel MDM2 ligands were identified by virtual
screening of a library of chalcones, and analysis of their activities as
p53–MDM2 inhibitors was confirmed using a yeast-based cell assay.
After analyzing their tumor cell growth inhibitory potential in a panel
of human tumor cell lines, the activity of the most potent chalcones
was further studied in the non-small cell lung cancer cell line
(NCI-H460). The effect on cell proliferation, cell cycle, and apoptosis,
as well as cellular levels of p53 and some of its downstream targets, was
assessed for the most promising chalcone derivatives.
2. Material and methods
2.1. Docking of chalcones onto MDM2
The structures of 136 chalcones were drawn using Chemsketch
(Advanced Chemistry Development, Inc. (ACD/Labs),Canada); the structure of the known p53–MDM2 inhibitor
nutlin-3A was obtained from Pubchem (Wang et al., 2009).
The 3-Dimensional (3D) structures of the chalcones and
control were minimized by the semi-empirical Polak–Ribiere
conjugate gradient method (RMS < 0.1 kcal A˚1 mol1)
using HyperChem 7.5 (Froimowitz, 1993).
The 3D structure of MDM2 was obtained from PDB (PDB
id: 4HG7). Docking simulations between MDM2 and the
small molecules were undertaken in AutoDock Vina (Scripps
Research Institute, USA) (Seeliger and de Groot, 2010; Trott
and Olson, 2009). AutoDock Vina considered the target con-
formation as a rigid unit while the ligands were allowed to
be flexible and adaptable to the target. Vina searched for the
lowest binding affinity conformations and returned nine differ-
ent conformations for each ligand. AutoDock Vina was run
using an exhaustiveness of 8 and a grid box with the dimen-
sions 25.0, 20.0, 20.0, engulfing the cavity occupied by the crys-
tallographic nutlin-3A (PDB id: 4HG7) (Anil et al., 2013).
Conformations and interactions were visualized using PyMOL
version 1.3 (Lill and Danielson, 2010). In order to validate the
docking approach for the protein structure used, the respective
co-crystallized known inhibitor, nutlin-3A (PDB id: 4HG7),
was docked to the active site using Autodock Vina (supple-
mentary data Fig. 1A); and a relation between docking scores
and p53–MDM2 inhibitory activity was established (supple-
mentary data Fig. 1B).
2.2. Synthesis
MW reactions were performed using a glassware setup for
atmospheric pressure reactions and a 100 mL Teflon reactor
(internal reaction temperature measurements with a fiber-
optic probe sensor) and were carried out using an Ethos
MicroSYNTH 1600 Microwave Labstation from Milestone.
The reactions were monitored by thin-layer chromatography
(TLC). Purifications of compounds were carried out by flash
chromatography using Macherey–Nagel silica gel 60 (0.04–
0.063 mm), and preparative thin-layer chromatography
(TLC) using Macherey–Nagel silica gel 60 (GF254) plates.
Melting points were obtained in a Ko¨fler microscope and are
uncorrected. 1H and 13C NMR spectra were taken in CDCl3
at room temperature, on Bruker Avance 300 and 500 instru-
ments (300.13 MHz or 500.13 MHz for 1H and 75.47 MHz
or 125.77 MHz for 13C). Chemical shifts are expressed in d
(ppm) values relative to tetramethylsilane (TMS) as an internal
reference; 13C NMR assignments were made by 2D (HSQC
and HMBC) NMR experiments (long-range C, H coupling
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recorded as ESI (electrospray ionization) mode on MicrOTOF
spectrometer at C.A.C.T.I.-University of Vigo, Spain. 1-(2,4-
Dihydroxy-3-propylphenyl)ethan-1-one, 3,4,5-trimethoxy,
3,4-dimethoxy-, 3,5-dimethoxy, 2,4-dimethoxy, 2,3-
dimethoxy, and 2,4,5-trimethoxybenzaldehydes were pur-
chased from Sigma Aldrich (Spain). The following materials
were synthesized and purified by the described procedures.
2.2.1. Synthesis of 1-(2-hydroxy-4-methoxy-3-propylphenyl)
ethan-1-one (1)
To a solution of 1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one
(2) (3.000 mmol, 0.584 g) in anhydrous acetone (20 mL) was
added potassium carbonate (6 mmol, 0.8292 g). Dimethyl sul-
fate (342.7 lL) was added dropwise and the mixture was
allowed to stir (4 h) at reflux and under nitrogen atmosphere.
The reaction was quenched by the addition of about 80 mL of
distilled water and acetone was evaporated. To the aqueous
phase 1 M HCl was added to pH 2–3 and the solution
extracted with ethyl acetate (3  100 mL). The organic phase
was washed with brine (2  50 mL) and dried over anhydrous
sodium sulfate. The organic solvent was evaporated and
1-(2-hydroxy-4-methoxy-3-propylphenyl)ethan-1-one (1) was
obtained in quantitative yield.
2.2.1.1. 1-(2-hydroxy-4-methoxy-3-propylphenyl)ethan-1-one
(1). 1H NMR (CDCl3, 300.13 MHz): d 12.73 (1H, s, 2-OH),
7.60 (1H, d, J= 8.9 Hz, H-6), 6.45 (1H, d, J= 8.9 Hz, H-5),
3.88 (3H, s, 4-OCH3), 2.62 (2H, t, J= 6.0 Hz, H-1
00), 2.57
(3H, s, COCH3), 1.46–1.59 (2H, m, H-2
00), 0.97 (3H, t,
J= 7.4 Hz, H-300). 13C NMR (CDCl3, 75.47 MHz): d 202.9
(CO), 163.5 (C-2), 162.0 (C-4), 130.0 (C-6), 118.3 (C-1),
114.2 (C-3), 101.9 (C-5), 55.7 (OCH3), 26.3 (COCH3), 24.3
(C-100), 21.9 (C-200), 14.2 (C-300).
2.2.2. General procedure for the synthesis of chalcones 3–8
To a solution of 1-(2-hydroxy-4-methoxy-3-propylphenyl)eth
an-1-one (1) (1.000 mmol, 0.208 g) in methanol was added an
aqueous solution of sodium hydroxide (60%) to pH 13–14.
Then, a solution of 2 mmol of the appropriate benzaldehyde
in methanol was slowly added to the reaction mixture. The
reaction was submitted to successive 15 min periods of micro-
wave irradiation of 180 W of power. Total irradiation time was
60 (chalcone 8) or 90 min (chalcones 3–7) and the final temper-
ature was 75 C. The solution was extracted with chloroform
(3  50 mL). The combined organic layers were rinsed with
brine and water, dried over anhydrous sodium sulfate and
evaporated under reduced pressure. The obtained residues
were purified as indicated below for the referred chalcones.
2.2.2.1. (E)-1-(2-hydroxy-4-methoxy-3-propylphenyl)-3-(3,4,
5-trimethoxyphenyl)prop-2-en-1-one (3). Purified by flash col-
umn chromatography (n-hexane:ethyl acetate, 9:1) followed
by crystallization (chloroform). Yield: 37% as yellow crystals;
mp (chloroform): 126.0–127.2 C; 1H NMR (CDCl3,
300.13 MHz): d 13.38 (1H, s, 20-OH), 7.81 (1H, d,
J= 9.2 Hz, H-60), 7.80 (1H, d, J= 15.0 Hz, H-b), 7.49 (1H,
d, J= 15.0 Hz, H-a), 6.87 (2H, s, H-2,6), 6.51 (1H, d,
J= 9.2 Hz, H-50), 3.94 (6H, s, 3-,5-OCH3), 3.91 (6H, s, 4-,40-
OCH3), 2.66 (2H, t, J= 7.7 Hz, H-1
00), 1.59–1.52 (2H, m,
H-200), 0.97 (3H, t, J= 7.4 Hz, H-300); 13C NMR (CDCl3,75.47 MHz): d 192.1 (CO), 163.6 (C-40), 163.3 (C-20), 153.5
(C-3,5), 144.2 (C-b), 140.4 (C-4), 130.4 (C-1), 129.0 (C-60),
119.8 (C-a), 118.6 (C-30), 114.4 (C-10), 105.7 (C-2,6), 102.0
(C-50), 61.0 (4-OCH3), 56.2 (3,5-OCH3), 55.7 (40-OCH3), 24.4
(C-100), 21.9 (C-200), 14.2 (C-300); ESI-HRMS (+) m/z: Anal.
Calc. for C22H27O6 (M+H)
+: 387.18022; found: 387.18050.
2.2.2.2. (E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-4-meth-
oxy-3-propylphenyl)prop-2-en-1-one (4). Purified by flash col-
umn chromatography (n-hexane:ethyl acetate, 9:1). Yield:
42% as yellow solid; mp (n-hexane: ethyl acetate): 122.6–
125.7 C; 1H NMR (CDCl3, 500.13 MHz): d 13.46 (1H, s, 20-
OH), 7.84 (1H, d, J= 15.4 Hz, H-b), 7.81 (1H, d,
J= 9.1 Hz, H-60), 7.48 (1H, d, J= 15.4 Hz, H-a), 7.25 (1H,
dd, J= 8.5, 1.9 Hz, H-6), 7.16 (1H, d, J= 1.9 Hz, H-2),
6.91 (1H, d, J= 8.5 Hz, H-5), 6.50 (1H, d, J= 9.1 Hz, H-
50), 3.97 (3H, s, 3-OCH3), 3.94 (3H, s, 4-OCH3), 3.90 (3H, s,
40-OCH3), 2.65 (2H, t, J= 7.6 Hz, H-100), 1.58–1.52 (2H, m,
H-200), 0.97 (3H, t, J= 7.3 Hz, H-300); 13C NMR (CDCl3,
125.77 MHz): d 192.2 (CO), 163.4 (C-40), 163.2 (C-20), 151.4
(C-4), 149.2 (C-3), 144.2 (C-b), 128.9 (C-60), 127.8 (C-1),
123.2 (C-6), 118.5 (C-30), 118.3 (C-a), 114.5 (C-10), 111.0 (C-
5), 110.1 (C-2), 101.9 (C-50), 56.0 (4-OCH3), 55.9 (3-OCH3),
55.7 (40-OCH3), 24.4 (C-100), 21.9 (C-200), 14.3 (C-300); ESI-
HRMS (+) m/z: Anal. Calc. for C21H25O5 (M+H)
+:
357.16965; found: 357.16957.
2.2.2.3. (E)-3-(2,3-dimethoxyphenyl)-1-(2-hydroxy-4-meth-
oxy-3-propylphenyl)prop-2-en-1-one (5). Purified by flash col-
umn chromatography (petroleum ether:diethyl ether, 5:5).
Yield: 35% as yellow solid; mp (petroleum ether: diethyl
ether): 103.0–104.5 C; 1H NMR (CDCl3, 500.13 MHz): d
13.39 (1H, s, 20-OH), 8.14 (1H, d, J= 15.6 Hz, H-b), 7.79
(1H, d, J= 9.0 Hz, H-60), 7.71 (1H, d, J= 15.6 Hz, H-a),
7.27 (1H, d, J= 8.0 Hz, H-6), 7.11 (1H, t, J= 8.0 Hz, H-5),
6.97 (1H, d, J= 8.0 Hz, H-4), 6.49 (1H, d, J= 9.0 Hz, H-
50), 3.90 (9H, s, 2-,3-,40-OCH3), 2.65 (2H, t, J= 7.6 Hz, H-
100), 1.52–1.58 (2H, m, H-200), 0.96 (3H, t, J= 7.4 Hz, H-300);
13C NMR (CDCl3, 75.47 MHz): d 192.6 (CO), 163.5 (C-40),
163.3 (C-20), 153.2 (C-3), 148.9 (C-2), 138.9 (C-b), 129.2 (C-
1), 129.1 (C-60), 124.2 (C-5), 122.3 (C-a), 119.8 (C-6), 118.5
(C-30), 114.5 (C-10), 114.1 (C-4), 102.0 (C-50), 61.3 (2-OCH3),
55.9 (3-OCH3), 55.7 (4
0-OCH3), 24.4 (C-100), 21.9 (C-200), 14.2
(C-300); ESI-HRMS (+) m/z: Anal. Calc. for C21H25O5 (M
+H)+: 357.16965; found: 357.16964.
2.2.2.4. (E)-1-(2-hydroxy-4-methoxy-3-propylphenyl)-3-(2,4,
5-trimethoxyphenyl)prop-2-en-1-one (6). Purified by flash col-
umn chromatography (petroleum ether:chloroform, 5:5) fol-
lowed by thin layer chromatography (petroleum ether:
chloroform, 2:8). Yield: 34% as dark yellow solid; mp (petro-
leum ether: diethyl ether): 106.0–107.0 C; 1H NMR (CDCl3,
500.13 MHz): d 13.60 (1H, s, 20-OH), 8.16 (1H, d,
J= 15.5 Hz, H-b), 7.80 (1H, d, J= 9.0 Hz, H-60), 7.57 (1H,
d, J= 15.5 Hz, H-a), 7.12 (1H, s, H-6), 6.53 (1H, s, H-3),
6.49 (1H, d, J= 9.0 Hz, H-50), 3.95 (3H, s, 4-OCH3), 3.92
(3H, s, 5-OCH3), 3.91 (3H, s, 2-OCH3), 3.89 (3H, s, 4
0-
OCH3), 2.65 (2H, t, J= 7.6 Hz, H-1
00), 1.59–1.49 (2H, m, H-
200), 0.97 (3H, t, J= 7.3 Hz, H-300); 13C NMR (CDCl3,
75.47 MHz): d 192.7 (CO), 163.2 (C-40), 163.1 (C-20), 154.7
(C-2), 152.5 (C-4), 143.1 (C-5), 139.5 (C-b), 128.9 (C-60),
118.4 (C-a), 118.3 (C-30), 114.6 (C-10), 111.6 (C-6), 108.9
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56.0 (5-OCH3), 55.6 (4
0-OCH3), 24.4 (C-100), 21.9 (C-200), 14.3
(C-300); ESI-HRMS (+) m/z: Anal. Calc. for C22H27O6 (M
+H)+: 387.18022; found: 387.18018.
2.2.2.5. (E)-3-(3,5-dimethoxyphenyl)-1-(2-hydroxy-4-meth-
oxy-3-propylphenyl)prop-2-en-1-one (7). Purified by flash col-
umn chromatography (n-hexane:ethyl acetate, 9:1). Yield:
37% as yellow solid; mp (n-hexane:ethyl acetate): 122.6–
125.7 C; 1H NMR (CDCl3, 500.13 MHz): d 13.33 (1H, s, 20-
OH), 7.79 (1H, d, J= 15.4 Hz, H-b), 7.78 (1H, d,
J= 9.0 Hz, H-60), 7.56 (1H, d, J= 15.4 Hz, H-a), 6.78 (2H,
d, J= 2.2 Hz, H-2,6), 6.53 (1H, t, J= 2.2 Hz, H-4), 6.50
(1H, d, J= 9.0 Hz, H-50), 3.90 (3H, s, 40-OCH3), 3.84 (3H, s,
3-OCH3), 3.80 (3H, s, 5
0-OCH3), 2.66 (2H, t, J= 7.6 Hz, H-
100), 1.59–1.53 (2H, m, H-200), 0.96 (3H, t, J= 7.3 Hz, H-300);
13C NMR (CDCl3, 75.47 MHz): d 192.2 (CO), 163.6 (C-40),
163.3 (C-20), 161.0 (C-3,5), 144.0 (C-b), 136.7 (C-1), 129.1 (C-
60), 121.1 (C-a), 118.5 (C-30), 114.4 (C-10), 106.4 (C-2,6), 102,5
(C-4), 102.0 (C-50), 55.7 (3,40-OCH3), 55.5 (5-OCH3), 24.4 (C-
100), 21.9 (C-200), 14.2 (C-300); ESI-HRMS (+) m/z: Anal. Calc.
for C21H25O5 (M+H)
+: 357.16965; found: 357.16909.
2.2.2.6. (E)-3-(2,4-dimethoxyphenyl)-1-(2-hydroxy-4-meth-
oxy-3-propylphenyl)prop-2-en-1-one (8). Purified by flash col-
umn chromatography (n-hexane:ethyl acetate, 9:1). Yield:
33% as yellow solid; mp (n-hexane:ethyl acetate): 152.0–
152.5 C; 1H NMR (CDCl3, 300.13 MHz): d 8.12 (1H, d,
J= 15.5 Hz, H-b), 7.80 (1H, d, J= 8.9 Hz, H-60), 7.64 (1H,
d, J= 15.5 Hz, H-a), 7.58 (1H, d, J= 8.6 Hz, H-6), 6.55
(1H, dd, J= 8.6, 2.4 Hz, H-5), 6.49 (1H, d, J= 8.9 Hz, H-
50), 6.48 (1H, d, J= 2.4 Hz, H-3), 3.92 (3H, s, 40-OCH3),
3.89 (3H, s, 4-OCH3), 3.86 (3H, s, 2-OCH3), 2.66 (2H, t,
J= 7.6 Hz, H-100), 1.62–1.49 (2H, m, H-200), 0.97 (3H, t,
J= 7.4 Hz, H-300); 13C NMR (CDCl3, 75 MHz): d 192.9
(CO), 163.2 (C-4,40), 163.0 (C-20), 160.4 (C-2), 139.8 (C-b),
131.1 (C-6), 128.9 (C-60), 118.6 (C-30), 118.4 (C-a), 117.1 (C-
1), 114.7 (C-10), 105.4 (C-5), 101.7 (C-50), 98.4 (C-3), 55.6 (40-
OCH3), 55.5 (2,4-OCH3), 24.4 (C-1
00), 21.9 (C-200), 14.3 (C-
300) (the d value for OH is not visible probably due to exchange
with hydrochloric acid in the solvent used, CDCl3); ESI-
HRMS (+) m/z: Anal. Calc. for C21H25O5 (M+H)
+:
357.16965; found: 357.16942.
2.2.3. Synthesis of chalcones 9–12, 16 and 17
Chalcones 9 (58%), 10 (34%), 11 (28%), 12 (26%), 16 (35%),
and 17 (53%) were synthesized and characterized according to
the previously described procedure (Neves et al., 2012a).
2.2.3.1. (E)-3-(4-(benzyloxy)phenyl)-1-(2,4-dihydroxyphenyl)
prop-2-en-1-one (9). 1H NMR (CDCl3, 300 MHz): d 13.47
(1H, s, 20-OH), 7.86 (1H, d, J= 15.3 Hz, H-b), 7.83 (1H, d,
J= 9.4 Hz, H-60), 7.62 (2H, d, J= 8.7 Hz, H-2,6), 7.46 (1H,
d, J= 15.3 Hz, H-a), 7.46–7.33 (5H, m, 4-OBn), 7.02 (2H,
d, J= 8.7 Hz, H-3,5), 6.44 (1H, dd, J= 9.4, 2.4 Hz, H-50),
6.42 (1H, d, J= 2.4 Hz, H-30), 5.88 (1H, br s, 40-OH), 5.13
(2H, s, 4-OCH2). ESI-HRMS (+) m/z: Anal. Calc for
C22H19O4 (M+H)
+: 347.1278; found: 347.1276.
2.2.3.2. (E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(3,4,5-tri-
methoxyphenyl)prop-2-en-1-one (10). 1H NMR (CDCl3,300 MHz): d 13.68 (1H, s, 20-OH), 7.80 (1H, d, J= 15.4 Hz,
H-b), 7.72 (1H, d, J= 8.9 Hz, H-60), 7.46 (1H, d,
J= 15.4 Hz, H-a), 6.86 (2H, s, H-2,6), 6.43 (1H, d,
J= 8.9 Hz, H-50), 5.78 (1H, br s, 40-OH), 3.93 (6H, s, 3,5-
OCH3), 3.91 (3H, s, 4-OCH3), 2.67 (2H, t, J= 7.7 Hz, H-
100), 1.68–1.56 (2H, m, H-200), 1.00 (3H, t, J= 7.4 Hz, H-300);
ESI-HRMS (+) m/z: Anal. Calc for C21H25O6 (M+H)
+:
313.1646; found: 313.1643.
2.2.3.3. (E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(2,4,5-tri-
methoxyphenyl)prop-2-en-1-one (11). 1H NMR (CDCl3,
300 MHz): d 13.89 (1H, s, 20-OH), 8.17 (1H, d, J= 15.5 Hz,
H-b), 7.72 (1H, d, J= 8.9 Hz, H-60), 7.55 (1H, d,
J= 15.5 Hz, H-a), 7.12 (1H, s, H-6), 6.53 (1H, s, H-3), 6.41
(1H, d, J= 8.9 Hz, H-50), 5.44 (1H, br s, 40-OH), 3.96 (3H,
s, 2-OCH3), 3.93 (3H, s, 5-OCH3), 3.92 (3H, s, 4-OCH3),
2.66 (2H, t, J= 7.7 Hz, H-100), 1.66–1.56 (2H, m, H-200); 1.00
(3H, t, J= 7.4 Hz, H-300). ESI-HRMS (+) m/z: Anal. Calc
for C21H25O6 (M+H)
+: 373.1646; found: 373.1643.
2.2.3.4. (E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(4-methoxy-
phenyl)prop-2-en-1-one (12). 1H NMR (CDCl3, 300 MHz): d
13.78 (1H, s, 20-OH), 7.86 (1H, d, J= 15.4 Hz, H-b), 7.72
(1H, d, J= 8.9 Hz, H-6’), 7.61 (2H, d, J= 8.8 Hz, H-2,6),
7.24 (1H, d, J= 15.4 Hz, H-a), 6.95 (2H, d, J= 8.8 Hz, H-
3,5), 6.41 (1H, d, J= 8.9 Hz, H-50), 5.39 (1H, br s, 40-OH),
3.87 (3H, s, 4-OCH3), 2.66 (2H, t, J= 7.7 Hz, H-1
00), 1.65–
1.58 (2H, m, H-200), 1.00 (3H, t, J= 7.4 Hz, H-300). ESI-
HRMS (+) m/z: Anal. Calc for C19H21O4 (M+H)
+:
313.1434; found: 313.1435.
2.2.3.5. (E)-1-(2,4-dihydroxyphenyl)-3-(3,4,5-trimethoxyphe-
nyl)prop-2-en-1-one (16). 1H NMR (CDCl3, 500 MHz): d
13.38 (1H, s, 20-OH), 7.85 (1H, d, J= 8.6 Hz, H-60), 7.81
(1H, d, J= 15.3 Hz, H-b), 7.45 (1H, d, J= 15.3 Hz, H-a),
6.87 (2H, s, H-2,6), 6.45 (1H, dd, J= 8.6, 2.5 Hz, H-50), 6.43
(1H, d, J= 2.5 Hz, H-30), 3.94 (6H, s, 3,5-OCH3), 3.91 (3H,
s, 4-OCH3). ESI-HRMS (+) m/z: Anal. Calc for C18H19O6
(M+H)+: 331.1176; found: 331.1177.
2.2.3.6. (E)-1-(2,4-dihydroxyphenyl)-3-(2,4,5-trimethoxyphe-
nyl)prop-2-en-1-one (17). 1H NMR (CDCl3, 500 MHz): d
8.18 (1H, d, J= 15.4 Hz, H-b), 7.84 (1H, d, J= 8.3 Hz, H-
60), 7.53 (1H, d, J= 15.4 Hz, H-a), 7.12 (1H, s, H-6), 6.53
(1H, s, H-3), 6.43 (1H, dd, J= 8.3, 2.5 Hz, H-50), 6.42 (1H,
d, J= 2.5 Hz, H-30), 3.96 (3H, s, 2-OCH3), 3.93 (3H, s, 5-
OCH3), 3.92 (3H, s, 4-OCH3) (the d value for OH is not visible
probably due to exchange with hydrochloric acid in the solvent
used, CDCl3); ESI-HRMS (+) m/z: Anal. Calc for C18H19O6
(M+H)+: 331.1176; found: 331.1175.
2.3. Biological evaluation
2.3.1. Yeast strains and growth conditions
For the yeast growth-inhibition assay, co-transformed Saccha-
romyces cerevisiae cells expressing human MDM2 and/or
human p53 and control yeasts (co-transformed with the empty
vectors pLS239 and pGADT7) obtained in previous work
(Leao et al., 2013) were used. For selection of co-
transformed yeasts, cells were routinely grown in a minimal
selective medium with 2% (w/w) glucose, 0.7% (w/w) yeast
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Sintra, Portugal) and all the amino acids required for yeast
growth (50 lg/mL) except leucine and tryptophan, to
approximately 1 optical density at 600 nm (OD600). To induce
expression of wt p53 and MDM2, yeasts were diluted to 0.05
OD600 into selective induction medium with 2% (w/w)
galactose and 2% (w/w) raffinose (instead of glucose), and
incubated at 30 C under continuous orbital shaking (200 r.
p.m.) for approximately 42 h (time required by control yeast,
to achieve 0.45 OD600). Yeast growth was analyzed by
counting the number of colony-forming units (CFU) per mL
(CFU/mL) after 2 days incubation at 30 C on Sabouraud
Dextrose Agar plates from Liofilchem (Frilabo, Porto,
Portugal).
2.3.2. Effects of compounds on yeast cell growth
Co-transformed yeast cells were incubated in selective
induction medium in the presence of 10 lM nutlin-3A (Sigma),
1–50 lM of each compound or 0.1% DMSO only, for approx-
imately 42 h, at 30 C, under continuous orbital shaking. Yeast
cell growth was analyzed as described in Section 3.3.1. Results
were estimated considering as 100% growth the number of
CFU obtained with the control yeast.
2.3.3. Studies in human tumor cell lines
2.3.3.1. Cell culture. The following human tumor cell lines were
used: MCF-7 (breast cancer), NCI-H460 (non-small cell lung
cancer), AGS (gastric cancer) and the HCT116 p53+/+ and
p53/ isogenic cells (colon cancer). The cell lines were rou-
tinely maintained in RPMI-1640 medium with UltraGlutamine
I and 25 mM Hepes (Lonza), supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Biowest) at 37 C in a
humidified atmosphere containing 5% CO2. Cell number and
viability were assessed using trypan blue (Sigma). All the
experiments were performed with exponentially growing cells
presenting more than 90% cell viability.
2.3.3.2. In vitro cell growth inhibition screening assay. Cells
were plated in a 5% FBS supplemented medium in 96-well
plates (5000 cells/well for MCF-7, NCI-H460 and HCT116
cells and 7500 cells/well for AGS cells) and then allowed to
adhere for 24 h. Cells were then treated with five serial dilution
concentrations of each compound (from a maximum
concentration of 150 lM). Following a 48 h incubation period,
cells were fixed in situ with 10% ice cold trichloroacetic acid,
washed and stained with Sulforhodamine B (SRB) (Neves
et al., 2011; Neves et al., 2012a, 2012b). The bound stain
was solubilized in 10 mM Tris-base and the absorbance was
measured at 510 nm in a multiwell plate reader (Biotek
Instruments Inc. Synergy Mx, USA). The effect of maximum
volume of DMSO (solvent, 0.25%) was analyzed in all
experiments.
2.3.3.3. Effect of compounds 3 and 4 in NCI-H460 viable cell
number, cell cycle profile, apoptosis and protein expression.
2.3.3.3.1. Cell treatments. NCI-H460 cells were plated in 6-well
plates (1  105 cells/well) in a 10% FBS supplemented med-
ium, at 37 C, in a humidified incubator with 5% CO2, for
24 h. Cells were then treated for 48 h to the GI50 and 2xGI50
concentrations of compounds 3 and 4, correspondingrespectively to 2.1 lM and 4.2 lM of compound 3 and
3.3 lM and 6.6 lM of compound 4. Cells were also incubated
with medium only (Blank) or with the highest volume of
DMSO used (0.11%). Following treatment, viable cell number
and viability were determined with the Trypan blue exclusion
assay and cells were further processed as follows.
2.3.3.3.2. Cell cycle profile. Following 48 treatment, cell pel-
lets were fixed in ice-cold 70% ethanol and stored at 4 C. For
analysis, cells were incubated in 5 lg/mL propidium iodide and
100 lg/mL RNase A (in PBS) for 30 min on ice. Analysis of
cellular DNA content was carried out using a BD Accuri C6
cytometer (BD Biosciences). The percentage of cells in the dif-
ferent phases of the cell cycle (G1, S and G2/M phases) was
carried out after exclusion of cell debris and aggregates, using
the FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR,
USA) (Cazal et al., 2013). At least 20,000 events were analyzed
for each of the conditions.
2.3.3.3.3. BrdU incorporation assay. Following 47 h treat-
ment, cells were incubated with 10 lM bromodeoxyuridine
(BrdU; Sigma) for 1 h. Cells were then trypsinized and fixed
in 4% paraformaldehyde (in PBS) for 30 min. Cytopsins were
prepared and cells were incubated for 20 min in 2 M HCl for
denaturation. After incubation with mouse anti-BrdU primary
antibody (1/10, Dako) for 1 h at room temperature and further
incubation with anti-mouse-Ig-FITC (1/100, Dako) for
30 min, at room temperature, slides were mounted with Vec-
tashield mounting medium with DAPI (Vector Laboratories).
BrdU incorporation was determined by counting a minimum
of 500 cells per slide using a fluorescence microscope
(DM2000; LEICA) (Preto et al., 2009).
2.3.3.3.4. Apoptosis. Following 48 h treatment, cellular
apoptosis levels were assessed using the ‘‘Human AnnexinV-
FITC/PI apoptosis” kit (Bender MedSystems) as previously
described (Neves et al., 2011). Briefly, cell pellets were resus-
pended in binding buffer (diluted in H2O) and incubated with
Annexin V-FITC and with propidium iodide. Samples were
analyzed using a BD Accuri C6 cytometer (BD Biosciences).
The FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR,
USA) was used and at least 20,000 events were analyzed for
each condition.
2.3.3.3.5. Protein expression. Total protein lysates were pre-
pared by lysing cells in Winman’s buffer (1% NP-40, 0.1 M
Tris–HCl pH 8.0, 0.15 M NaCl and 5 mM EDTA) with pro-
tease inhibitor cocktail (Roche) (Lima et al., 2006). Protein
content was quantified with DCTM Protein Assay kit (Biorad)
according to manufacturer’s instructions. Proteins were elec-
trophoretically separated on 12% SDS–PAGE gel and trans-
ferred into nitrocellulose membranes (Amersham).
Membranes were incubated with the following primary anti-
bodies: mouse anti-p53 (DO-1, 1:5000, Santa Cruz Biotechnol-
ogy), mouse anti-p21 (1:250, Calbiochem), mouse anti-PUMA
(1:500, Santa Cruz Biotechnology) and goat anti-Actin anti-
body (1:2000, Santa Cruz Biotechnology) and with the corre-
sponding secondary antibody: donkey anti-goat IgG-HRP
(1:2000, Santa Cruz Biotechnology) or goat anti-mouse IgG-
HRP (1:2000, Santa Cruz Biotechnology). Signal was detected
using AmershamTM ECL Western Blotting Detection Reagents
(GE Healthcare), the Amersham Hyperfilm ECL (GE Health-
care) and the Kodak GBX developer and fixer (Sigma). The
intensity of the bands obtained in each film was further ana-
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Rad, USA).
2.4. Statistical analysis
All data are presented as mean ± SEM from at least three
independent experiments. Statistical analysis was carried out
using an unpaired student’s t-test. * Indicates p 6 0.05 and
** p 6 0.01 between blank cells (cells treated with medium
only) and each treatment.
3. Results and discussion
3.1. Virtual screening
p53–MDM2 interaction is mediated by a well-defined
hydrophobic surface pocket in MDM2 and three key
hydrophobic residues in p53, namely Phe-19, Trp-23, and
Leu-26 (Kussie et al., 1996; Ma et al., 2005). Therefore,Table 1 Best scoring small molecules (from a virtual library of cha
target.
Ligand
(E)-1-(2-hydroxy-4-methoxy-3-propylphenyl)-3-(3,4,5-trimethoxyphenyl)p
(E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-4-methoxy-3-propylphenyl)pro
(E)-3-(2,3-dimethoxyphenyl)-1-(2-hydroxy-4-methoxy-3-propylphenyl)pro
(E)-1-(2-hydroxy-4-methoxy-3-propylphenyl)-3-(2,4,5-trimethoxyphenyl)p
(E)-3-(4-(benzyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (9)
(E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-e
(E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(2,4,5-trimethoxyphenyl)prop-2-e
(E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(4-methoxyphenyl)prop-2-en-1-on
(E)-3-(4-(benzyloxy)phenyl)-1-(2,4-dihydroxy-3-methylphenyl)prop-2-en-1
(E)-1-(2,4-dihydroxy-3-propylphenyl)-3-(4-(trifluoromethyl)phenyl)prop-2
(E)-3-(2-chlorophenyl)-1-(2,4-dihydroxy-3-propylphenyl)prop-2-en-1-one
Nutlin-3A (control)
a Molecules with LogP greater than 5 (excluded for not obeying Lipins
water partition coefficient implemented by Ghose and Crippen (Ghose a
Scheme 1 Synthesis of chalcones 3–8. The numsmall-molecules with a chalcone scaffold may be designed in
order to block this interaction to reactivate p53 in cells harbor-
ing wt p53 (Fotouhi and Graves, 2005; Secchiero et al., 2011).
As a part of an ongoing effort to identify new disruptors of
the MDM2–p53 interaction for potential drug development
(Leao et al., 2013), virtual screening was performed on 136
newly designed chalcones. This library of virtual chalcones
was submitted to a docking study using MDM2 as target. Sev-
eral chalcones presented docking scores similar to the known
p53–MDM2 inhibitor nutlin-3A. The best scoring molecules
(docking scores 6 7 kcal/mol) are represented on Table 1.
The docking scores of the 125 chalcones with docking
scores > 7 kcal/mol are represented in Supplementary
Table 1. The chalcones with docking scores lower or equal
to 7 kcal/mol which respected Lipinski rule of five were sub-
sequently synthetized. In order to understand the relationship
between docking scores, docking poses, and% of p53–MDM2
inhibitory activity, structure-related chalcones with lower
docking scores were also synthesized and tested.lcones) that resulted from a docking simulation using MDM2 as
Docking score (kcal/mol)
rop-2-en-1-one (3) 7.5
p-2-en-1-one (4) 7.5
p-2-en-1-one (5) 7
rop-2-en-1-one (6) 7
8.3
n-1-one (10) 7.5
n-1-one (11) 7.1
e (12) 7
-one (13)a 8.3
-en-1-one (14)a 7.8
(15)a 7.7
7.6
ki rule of five). LogP was determined using the atom-based octanol–
nd Crippen, 1987).
bering used concerns the NMR assignments.
Table 2 Effect of compounds on the inhibitory activity of
MDM2 on the p53-induced yeast growth inhibition.
Compounds Growth Inhibition (% of p53 effect)
DMSO 0.2 ± 4.2
Nutlin-3A 67.8 ± 3.3
3 79.4 ± 4.8
4 97.2 ± 6.3
5 63.7 ± 3.1
6 68.8 ± 2.2
7 19.4 ± 3.4
8 17.4 ± 1.9
9 77.9 ± 7.5
10 95.2 ± 6.8
11 78.3 ± 5.4
12 97.0 ± 4.7
16 0.2 ± 3.2
17 0.1 ± 2.9
Yeast cells expressing p53 and MDM2 were incubated in selective
medium in the presence of 10 lM compound or DMSO only, for
42 h. Nutlin-3A was used as positive control. The growth inhibition
obtained with yeast cells expressing only p53 treated with dimethyl
sulfoxide (DMSO) was considered 100%. Data are mean ± S.E.M.
of five independent experiments.
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Six new chalcone derivatives 3–8 were prepared by base-
catalyzed aldol reactions of 1-(2-hydroxy-4-methoxy-3-propyl
phenyl)ethan-1-one (1) with appropriately substituted ben-
zaldehydes as building blocks by MAOS, according to the
strategy illustrated on Scheme 1. 1-(2-Hydroxy-4-methoxy-3-
propylphenyl)ethan-1-one (1) was synthesized by the methyla-
tion of 1-(2,4-dihydroxy-3-propylphenyl)ethan-1-one (2) with
dimethyl sulfate in presence of anhydrous potassium carbonate
and anhydrous acetone (Scheme 1). The structure elucidation
of compound 1 was established by 1H and 13C NMR tech-
niques and data were in accordance to the previously reported
(Alves de Lima et al., 1982; Alves de Lima and Delle Monache,
1978).
Chalcones 9–12, 16, and 17 were synthesized according to
the procedure described elsewhere (Neves et al., 2012a). The
structure elucidation of compounds 3–8, 9–12, 16 and 17 was
established on basis of HRMS and NMR techniques. 13C
NMR assignments were determined by 2D heteronuclear sin-
gle quantum correlation (HSQC) and heteronuclear multiple
bond correlation (HMBC) experiments. The appearance in
the 1HNMR spectra of two doublets with a coupling constant
(JHa-Hb) of 15.0–15.6 Hz characteristic of a (E)-configuration
instead of 12–13 Hz observed for Z isomers (Iwata et al.,
1997) allowed to confirm that the ethylene moiety in the enone
linkage is in the (E)-configuration according to previously
reported (Balsera et al., 2014; Iwata et al., 1997; Khan et al.,
2015; Neves et al., 2012a, 2012b).
3.3. Biological evaluation
3.3.1. Effect in yeast-based screening assay
The best scoring chalcones (docking scores 6 7 kcal/mol),
which did respect Lipinski rules (AlogP > 5, H-bond
donors 6 5, H-bond acceptors 6 10, and molecular
weight < 500), including the newly synthesized chalcones 3–6
and those chalcones previously reported by some of us as
growth inhibitors of human tumor cell lines (9–12) (Neves
et al., 2012a) were here tested as p53–MDM2 interaction
inhibitors. This was carried out using a yeast-based assay pre-
viously developed to screen for potential inhibitors of the p53–
MDM2 interaction (Leao et al., 2013). In addition, chalcones
7, 8, 16, and 17, with lower docking scores were also tested in
yeast, in order to understand the relationship between docking
scores, docking poses, and% of growth inhibition (Table 2).
The effectiveness of this yeast assay was recently demonstrated
by the discovery of a new inhibitor of the p53–MDM2 interac-
tion with a xanthone (Leao et al., 2013) and an oxazoloisoin-
dolinone (Soares et al., 2015) scaffold. In this yeast assay, the
expression of human wt p53 induces yeast growth inhibition,
which is abolished by co-expression with human MDM2
(Leao et al., 2013). Inhibitors of the p53–MDM2 interaction,
such as nutlin-3A (positive control), reduce the impact of
MDM2 on p53 activity, thus restoring the p53-induced yeast
growth inhibition. Notably, these small molecules do not inter-
fere with the activity of p53 when expressed alone (Leao et al.,
2013). Using this approach, the effect of 1–50 lM of com-
pounds (Table 2) was evaluated using as endpoint the
MDM2-dependent reduction of p53-induced yeast growth
inhibition. From the concentration–response curves obtainedfor the tested compounds, 10 lM was selected as the lowest
concentration at which a higher reduction of the MDM2 effect
was obtained without interfering with the growth of control
yeast (empty vectors). Among the tested compounds, only
chalcones 3–6 and 9–12 caused a significant reversion of the
inhibitory effect of MDM2 on p53-induced yeast growth inhi-
bition, exhibiting a similar (compounds 5 and 6) or higher
(compounds 3, 4, 9–12) effect when compared to nutlin-3A
(Table 2). Compounds 3–6 and 9–12 therefore behaved as
potential inhibitors of the p53–MDM2 interaction. On the
other hand, compounds 7, 8, 16 and 17 were inactive in the
yeast assay. It must be noted, that compounds 3–6 and 9–12
did not interfere with the activity of p53 or MDM2 when
expressed alone, nor with the growth of control yeast (vector)
(data not shown).
From the 11 compounds predicted by docking studies to be
potential p53–MDM2 inhibitors, eight proved to be effective
as p53–MDM2 interaction inhibitors in this yeast assay (com-
pounds 3–6 and 9–12, 73% success). As expected, chalcones 7,
8, 16, and 17 which presented the lowest docking scores (dock-
ing scores > 7 kcal/mol) were found to be inactive or pre-
sented low/residual activity in the yeast assay (Table 2).
3.3.2. Effect on human tumor cell lines
3.3.2.1. In vitro cell growth inhibitory activity. In a previous
study, two of the most effective p53–MDM2 inhibitors (10
and 12) were already shown to have in vitro cell growth inhibi-
tory activity in wt p53 human tumor cell lines (Neves et al.,
2012a). In this study, compound 10 presented a concentration
required to reduce growth rates to 50% of the maximum rate
(GI50) lower than 9 lM and compound 12 presented GI50 con-
centrations lower than 47 lM. In the present study, the cell
growth inhibitory activities of two of the newly synthesized
and most effective p53–MDM2 inhibitors (chalcones 3 and
4) were analyzed in a panel of human tumor cell lines which
included: breast adenocarcinoma MCF-7, non-small cell lung
cancer NCI-H460 and gastric adenocarcinoma AGS (all hav-
Table 3 GI50 values determined for chalcones 3 and 4 following 48 h of treatment.
GI50 (lM)
MCF-7 NCI-H460 AGS HCT116+/+ HCT116/
Nutlin-3A – – – 3.2 ± 0.1 24.0 ± 0.7
3 2.3 ± 0.1 2.1 ± 0.1 3.2 ± 0.3 2.6 ± 0.2 3.4 ± 0.1
4 3.6 ± 0.3 3.3 ± 0.2 4.5 ± 0.4 5.9 ± 0.4 7.2 ± 1.1
Values, obtained with the Sulforhodamine B assay, refer to the mean ± SEM of at least three independent experiments. The maximum DMSO
concentration (0.25%) did not interfere with cell growth (data not shown). Doxorubicin was used as a positive control (GI50: 34.8 ± 7.4 nM in
MCF-7, 44.8 ± 13.2 nM in NCI-H460, 59.6 ± 5.1 nM in AGS, 105.5 ± 10.1 nM in HCT-116+/+ and >150 nM in HCT-116/ cells). Values
were not determined (–).
Figure 1 Dose–response curves for compounds 3 (A) and 4 (B),
analyzed with SRB assay. HCT116+/+ (dashed line) and
HCT116/ (full line) were treated for 48 h with the compounds.
Results are the mean ± SEM of, at least, 3 independent
experiments.
Figure 2 Effect of chalcones 3 and 4 on NCI-H460 viable cell
number, analyzed with the trypan blue exclusion assay. Cells were
treated for 48 h with the GI50 and 2  GI50 concentrations of
chalcone 3 (2.1 and 4.2 lM, respectively) and 4 (3.3 and 6.6 lM,
respectively) for 48 h. Results are presented as % of viable cells in
relation to blank (medium only) and are the mean ± SEM of 4
independent experiments. * P 6 0.01 treatment vs. Blank.
Figure 3 Effect of chalcones 3 and 4 in NCI-H460 cells
proliferation. Cells were treated for 48 h with: medium only
(Blank), the GI50 and 2  GI50 concentrations of chalcone 3 (2.1
and 4.2 lM, respectively) and 4 (3.3 and 6.6 lM, respectively) or
with the highest DMSO concentration. Results are the mean
± SEM of the percentage of BrdU-incorporating cells, from at
least 3 independent experiments. * P 6 0.05 treatment vs. Blank.
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HCT116 cell lines, p53+/+ and p53/ (Table 3; Fig. 1).
Results showed that the investigated chalcones inhibited the
growth of all the tested cell lines, even of the cell line without
p53 (HCT116/). In fact, contrary to Nutlin-3A, no
differences were observed between the GI50 concentrations of
chalcones 3 and 4 in p53+/+ and p53/ HCT116 cell
lines (Table 3), Therefore, in addition to the potential
p53–MDM2 inhibitory effect of these compounds, other mech-
anisms of action may be involved in the growth inhibitory
activity observed in human tumor cell lines. In order to
Figure 4 Effect of chalcones 3 and 4 in NCI-H460 cell cycle
profile. Cells were treated for 48 h with: medium only (Blank), the
GI50 and 2  GI50 concentrations of chalcone 3 (2.1 and 4.2 lM,
respectively) and 4 (3.3 and 6.6 lM, respectively) or with the
highest DMSO concentration. Results are the mean ± SEM of 3
independent experiments. * P 6 0.01 treatment vs. Blank.
Table 4 Percentage of apoptosis in NCI-H460 cells following
treatment with chalcones 3 and 4.
% Apoptosis
Blank 9.8 ± 1.1
DMSO 10.0 ± 0.4
3 2.1 lM 9.5 ± 0.9
4.2 lM 10.1 ± 1.1
4 3.3 lM 15.2 ± 2.5
6.6 lM 24.3 ± 3.8a
Values refer to mean ± SEM of at least 4 independent experiments.
a P 6 0.05 between treatment vs. Blank.
Figure 5 Effects of chalcones 3 and 4 on the levels of p53, p21, and
PUMA inNCI-H460 cells. Cells were treated for 48 h with: medium
only (Blank), the GI50 and 2  GI50 concentrations of chalcone 3
(2.1 and 4.2 lM, respectively) and 4 (3.3 and 6.6 lM, respectively) or
with the highest DMSO concentration. Actin was used as loading
control. (A) Images are representative of at least 3 independent
experiments. (B)Densitometry analysis of theWesternblots.Results
are expressed after normalization of the values obtained for each
proteinwith the values obtained forActin (in relation toBlank cells).
Each bar represents the mean ± SEM from, at least, 3 independent
experiments. * P 6 0.05 and ** P 6 0.01 treatment vs. Blank.
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4 could occur through p53-dependent pathway activation,
their effect was then further investigated in the NCI-H460
cells.
3.3.2.2. Effect on NCI-H460 viable cell number. As expected,
treatment with chalcones 3 and 4 significantly decreased
NCI-H460 viable cell number, in a dose-dependent manner
(Fig. 2). This was observed by counting the number of viable
cells with trypan blue exclusion assay 48 h following treatment
with the GI50 and 2  GI50 concentrations of chalcone 3 (2.1
and 4.2 lM, respectively) and 4 (3.3 and 6.6 lM, respectively).
Treatment with DMSO had no effect on cellular viability at
the highest concentration tested.
3.3.2.3. Effect on NCI-H460 cellular proliferation and cycle
profile. The BrdU incorporation assay was carried out to assess
the effect of both chalcones in cellular proliferation. A clear
and statistically significant reduction in the levels of prolifera-
tion was observed on NCI-H460 cells treated with chalcone 4
(Fig. 3). This was detected by a reduction in the percentage of
BrdU-incorporating cells from 33.0% (Blank) to 18.0%
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analyzed). Regarding chalcone 3, a small decrease in prolifer-
ation (to 25.4%) was noticed with the highest concentration
tested (4.2 lM) but was not considered statistically significant.
Furthermore, in order to estimate the percentage of cells in
the different phases of the cell cycle, NCI-H460 cells treated
with both chalcones were analyzed by flow cytometry after pro-
pidium iodide staining. As previously observed for the BrdU
incorporation assay, while no alterations were observed in the
cell cycle profile of NCI-H460 cells following treatment with
chalcone 3, treatment with chalcone 4 resulted in statistically
significant alterations of the NCI-H460 cell cycle profile
(Fig. 4). A statistically significant increase in the percentage
of cells at the G0/G1 phase, from 56.3% (Blank) to 61.9%
and 68.0%, was observed after treatment with chalcone 4 at
3.3 lM and 6.6 lM, respectively. This was accompanied by a
decrease in the percentage of cells in the S phase, from 25.2%
(Blank) to 17.2% after treatment with 6.6 lM chalcone 4.
3.3.2.4. Effect on NCI-H460 cellular apoptosis. To evaluate if
induction of apoptosis was also involved in the decreased cel-
lular viability observed after treatment with both chalcones,
flow cytometric analysis was carried out after labeling cells
with Annexin V-FITC/PI. Results showed that chalcone 4
induced apoptosis. This was observed by a dose-dependent
increase in the levels of apoptosis to 15.2% and to 24.3%, after
treatment with 3.3 lM and 6.6 lM of chalcone 4, respectively
(Table 4).
3.3.2.5. Effect on the levels of p53, p21, and PUMA. Since the
previous results showed that chalcone 4 caused cell cycle arrest
(mainly at the G0/G1 phase) and induced apoptosis in NCI-
H460 cells, which was in agreement with the fact that these
compounds were potential inhibitors of p53–MDM2 interac-
tion in the yeast cell model, the expression levels of p53 protein
and of some of its downstream targets, p21 and PUMA, were
analyzed (Fig. 5).
Results showed an increase in the levels of p53, mainly after
treatment with chalcone 4 (Fig. 5). Importantly, the levels of
p21 and PUMA were also increased in cells treated withFigure 6 (A) Binding mode of crystallographic p53 (for simplification
sticks). (B)MDM2 (solid surface) interacting with p53 (transparent sur
into three corresponding pockets on the protein. (A) The most pot
represented in blue sticks) docked into MDM2 structure, as predicted b
(blue sticks) in the binding site of MDM2. Structural data were obtaine
surface, where carbon, oxygen, nitrogen, and sulfur are represented in g
depicted with a dashed red line. Residues involved in other interactionchalcone 4, further supporting the hypothesis of p53 activation
following treatment with chalcone 4.
3.4. Docking studies
Chalcones 3 and 4 were further analyzed in terms of docking
poses and residues involved in the p53–MDM2 potential inter-
action (Fig. 6).
AutoDock Vina was the software chosen to predict docking
conformations and scores, as it has been described as being the
best software in predicting crystallographic p53–MDM2 inhi-
bitor poses (RMSD< 1.0 A˚) by redocking tests (Bharatham
et al., 2014). This was further confirmed by the RMSD com-
parison between crystallographic and docked nutlin-3A (sup-
plementary data Fig. 1A) and by the establishment of a
linear relation between docking scores and% growth inhibition
(supplementary data Fig. 1B).
The alpha-helical p53 peptide (residues 18–26) binds to a
deep hydrophobic cleft within the amino-terminal domain of
MDM2 (Chen et al., 2005). The binding site consists of a larger
pocket for Phe-19 and Trp-23 of p53 and a smaller pocket for
Leu-26 of p53 (Kalid and Ben-Tal, 2009) (Fig. 6A). Both pock-
ets are mainly hydrophobic. While searching for a chemical
moiety that could mimic the interaction between those p53
residues and MDM2, the methoxy-benzene rings of chalcones
were found to perfectly mimic the hydrophobic and hydrogen-
bonding interactions.
Fig. 6B shows the most stable binding poses of compounds
3 and 4 as suggested by the docking protocol. Compound 4
(Fig. 6C), the most active chalcone in the yeast assay and also
the one that was predicted to bind more stably in silico to
MDM2 binding pocket, establishes two hydrogen bond inter-
actions, parallel displaced stacking interactions, dipole–in-
duced dipole and van der Waals interactions, and mimics the
key hydrophobic residues of p53 when bound to MDM2.
One of the rings of the chalcone moiety of 4 occupies the
Leu-26 subpocket and forms two hydrogen bond interactions
with the protein. The other ring occupies the subpockets
Phe-19/Trp-23. This expanded conformation and scaffold ori-
entation in the cleft where p53 is supposed to bind, allows, only residues Phe-19, Trp-23, and Leu-26, are represented as red
face) via Phe-19, Trp-23, and Leu-26 (red sticks) side chains that fit
ent chalcones tested as p53–MDM2 interaction inhibitors (3, 4;
y the docking studies. (C) Predicted binding poses of compound 4
d from PDB structures 4HG7 and 1YCR. MDM2 is represented as
reen, red, blue, and yellow, respectively. Hydrogen interactions are
s are represented as green sticks.
4160 D. Pereira et al.additional interactions to be formed, strengthening the bond-
ing. Although no hydrogen interactions are predicted to be
established between 4 and subpockets Phe-19 and Trp-23
(Fig. 6C), induced dipole–permanent dipole, hydrophobic,
and van der Waals interactions occur between the substituted
chalcone rings and those subpockets. These types of interac-
tions are also described as being important for MDM2:p53
complexation (Zhao et al., 2015). However, Trp-23 is only par-
tially occupied by 4 (only Leu-54 establishes interaction with
the small molecule), leaving most of the pocket empty
(Fig. 6C). The inactive derivatives (7 and 8) and the derivatives
with low activity in the yeast assay are predicted to bind to
MDM2 in a different location and conformation (not shown).
From the docking results, it should be highlighted that more
hindered rings, with methoxyl and propyl substituents are pre-
dicted to orient the molecule in the binding site in a more
expanded conformation, occupying a larger volume of the
binding pocket and establishing more hydrogen and van der
Waals interactions. This information could lead to a new fam-
ily of chalcones, which may bind with more affinity to the
Mdm2 protein; from the docking results it is induced that more
hindered A rings, with additional polar groups at positions 5
and 6, would allow the establishment of the lacking hydrogen
interactions with Trp-23 subpocket.
4. Conclusion
In this work, using virtual screening followed by analysis of the biolog-
ical activity of the selected compounds in a yeast-based screening
assay, eight chalcones (3–6 and 9–12) were identified for the first time
as p53–MDM2 interaction inhibitors. The in vitro antitumor activity of
two of the most effective compounds (3 and 4) was further confirmed
in human tumor cell lines, in which chalcone 4 growth inhibitory effect
was clearly associated to an activation of the p53 pathway. Neverthe-
less, these compounds might have other mechanisms of action which
are independent from p53, which would explain the similar GI50 con-
centrations obtained in the HCT116 p53+/+ and p53/ isogenic cells.
The p53-independent mechanisms that may also be implicated in their
mechanism of action need further confirmation. In the future, other
chalcone derivatives with n-propyl groups at ring A, and with addi-
tional rings linked to ring B will be synthetized and tested. The results
obtained from this study will be valuable for the rational design of
novel and potent p53–MDM2 inhibitors.
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